Novel Potential Therapeutic Targets of PTPN Families for Lung Cancer

Abstract

Despite the treatment of lung adenocarcinoma (LUAD) having partially improved in recent years, LUAD patients still have poor prognosis rates. Therefore, it is especially important to explore effective biomarkers and exploit novel therapeutic developments. High-throughput technologies are widely used as systematic approaches to explore differences in expressions of thousands of genes for both biological and genomic systems. Recently, using big data analyses in biomedicine research by integrating several high-throughput databases and tools, including The Cancer Genome Atlas (TCGA), cBioportal, Oncomine, and Kaplan–Meier plotter, is an important strategy to identify novel biomarkers for cancer therapy. Here, we used two different comprehensive bioinformatics analysis and revealed protein tyrosine phosphatase non-receptor type (PTPN) family genes, especially PTPN1 and PTPN22, were downregulated in lung cancer tissue in comparison with normal samples. The survival curves indicated that LUAD patients with high transcription levels of PTPN5 were significantly associated with a good prognosis. Meanwhile, Gene Ontology (GO) and MetaCore analyses indicated that co-expression of the PTPN1, PTPN5, and PTPN21 genes was significantly enriched in cancer development-related pathways, including GTPase activity, regulation of small GTPase-mediated signal transduction, response to mechanical stimuli, vasculogenesis, organ morphogenesis, regulation of stress fiber assembly, mitogen-activated protein kinase (MAPK) cascade, cell migration, and angiogenesis. Collectively, this study revealed that PTPN family members are both significant prognostic biomarkers for lung cancer progression and promising clinical therapeutic targets, which provide new targets for treating LUAD patients.

Penetrating Exploration of Prognostic Correlations of the FKBP Gene Family with Lung Adenocarcinoma

“…GEPIA 2 ( , accessed on 22 November 2021) is a beneficial bioinformatics database that offers precise analyses of transcriptional levels of mRNA expressions for 8587 normal tissues and 9736 cancer samples from The Genotype-Tissue Expression (GTEx) project ( , accessed on 22 November 2021) and The Cancer Genome Atlas (TCGA) ( , accessed on 22 November 2021) [ 43 , 45 , 46 ]. GEPIA 2 supplies major functions including gene expression analyses, gene correlation analyses, survival analyses, similar gene predictions, and dimensionality reduction analyses.…”

Comprehensive multimodal and multiomic profiling reveals epigenetic and transcriptional reprogramming in lung tumors

“…Pathways that were associated with NSCLC development were found to be over-represented by SPDEF regulatees, highlighting their potential relevance in the disease progression. Specifically, “SUMOylation of ubiquitinylation proteins” pathway emerged due to the escalated activities of PIAS1 62 , SEH1L, and NUP37 63 ; and “Regulation of IFN gamma signaling” pathway for PIAS1 62 , PTPN2 64 , and STAT1 65 activities ( Figure 6D ).…”